stockmarketproxy
/
CORTNasdaq SEC EDGAR

CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations·REDWOOD CITY, CA·FY end 12/31·CIK 1088856
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$761.4M$675.0M$482.4M$401.9M$366.0M
Gross Profit——————
Operating Income$44.8M$137.0M$107.3M$112.6M$124.5M
Net Income$99.7M$141.2M$106.1M$101.4M$112.5M
Operating CF$142.0M$198.1M$127.0M$120.3M$167.9M
Capex$211.0K$2.2M$139.0K$413.0K$469.0K
Free Cash Flow$141.8M$195.9M$126.9M$119.9M$167.4M
Buybacks$172.9M$15.7M———
Dividends——————
Gross Margin——————
Operating Margin5.9%20.3%22.2%28.0%34.0%
Net Margin13.1%20.9%22.0%25.2%30.7%
FCF Margin18.6%29.0%26.3%29.8%45.7%
R&D / Revenue33.5%36.6%38.2%32.6%31.1%
Effective Tax-49.9%12.6%14.8%12.7%10.0%
Debt / Equity——————
Buybacks / FCF122.0%8.0%———

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
CORT
46:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
CORT
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
CORT
13.1%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%